GSK

1,929.5

+0.86%↑

GSK

1,929.5

+0.86%↑

GSK

1,929.5

+0.86%↑

GSK

1,929.5

+0.86%↑

GSK

1,929.5

+0.86%↑

Home・Aandelen Lijst・Haleon PLC
Search

Haleon PLC

Open

SectorGezondheidszorg

344.9 0.52

Buy

Prijsupdate 26 mei 2026, 08:58 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

343

Max

346.2

Belangrijke statistieken

By Trading Economics

Inkomsten

403M

Verkoop

2.7B

K/W

Sectorgemiddelde

17.742

49.701

EPS

0.044

Dividendrendement

2.13

Winstmarge

14.708

Werknemers

24,535

EBITDA

697M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+24.1% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.13%

2.39%

Volgende Winsten

30 jul 2026

Volgende Ex Dividend datum

13 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

30B

Vorige openingsprijs

344.38

Vorige sluitingsprijs

344.9

Nieuwssentiment

By Acuity

8%

92%

6 / 345 Rangschikking in Healthcare

Haleon PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 07:48 UTC

Winsten

Sensodyne-Maker Haleon Revenue Rises on Oral Health Growth -- Update

DJ

Lezen

29 apr 2026, 06:39 UTC

Winsten

Sensodyne-maker Haleon Revenue Rises on Oral Health Growth

DJ

Lezen

25 feb 2026, 07:55 UTC

Winsten

Panadol Maker Haleon Reports Revenue Slowdown Amid Weak Cold-And-Flu Season

DJ

Lezen

29 apr 2026, 08:05 UTC

Marktinformatie
Winsten

Haleon's North America Results Were Encouraging -- Market Talk

DJ

Lezen

29 apr 2026, 07:46 UTC

Marktinformatie
Winsten

Haleon's First-Quarter Results Align With Peers -- Market Talk

DJ

Lezen

29 apr 2026, 06:07 UTC

Winsten

Haleon: 1Q Emerging Markets Revenue Growth 4.3%

DJ

Lezen

29 apr 2026, 06:06 UTC

Winsten

Haleon: Q1 North America Organic Revenue Growth 1.0%

DJ

Lezen

29 apr 2026, 06:05 UTC

Winsten

Haleon 1Q Reported Revenue Growth 0.1%

DJ

Lezen

29 apr 2026, 06:04 UTC

Winsten

Analysts Saw Haleon 1Q Organic Revenue Growth 2.3%

DJ

Lezen

29 apr 2026, 06:04 UTC

Winsten

Haleon 1Q Organic Revenue Growth 2.2%

DJ

Lezen

29 apr 2026, 06:04 UTC

Winsten

Haleon 1Q Rev GBP2.86B

DJ

Lezen

29 apr 2026, 06:04 UTC

Winsten

Haleon Sees High-single Digit Adjusted Operating Profit Growth at Constant Currency in Medium Term

DJ

Lezen

29 apr 2026, 06:03 UTC

Winsten

Haleon Sees 4% to 6% Organic Rev Growth in Medium Term

DJ

Lezen

29 apr 2026, 06:03 UTC

Winsten

Haleon Expects a Broadly Neutral Foreign Exchange Translation Impact on Net Rev, Adj Oper Pft

DJ

Lezen

29 apr 2026, 06:02 UTC

Winsten

Haleon Sees 2026 Adjusted Effective Tax Rate c.24.5%

DJ

Lezen

29 apr 2026, 06:02 UTC

Winsten

Haleon: Sees 2026 Net Interest GBP255 Million

DJ

Lezen

29 apr 2026, 06:02 UTC

Winsten

Haleon Sees 2026 High-single Digit Adj Oper Pft Growth at Constant Currency

DJ

Lezen

29 apr 2026, 06:01 UTC

Winsten

Haleon Sees 2026 Organic Revenue Growth 3% to 5%

DJ

Lezen

25 feb 2026, 07:18 UTC

Winsten

Haleon 4Q Organic Revenue Growth 2.1%

DJ

Lezen

25 feb 2026, 07:17 UTC

Winsten

Haleon: GBP500M Allocated to Share Buybacks in 2026

DJ

Lezen

25 feb 2026, 07:16 UTC

Winsten

Haleon Sees 2026 High Single Digit Adj. Operating Profit Growth at Constant Currency

DJ

Lezen

25 feb 2026, 07:15 UTC

Winsten

Haleon Sees 2026 Organic Revenue Growth of 3% to 5%

DJ

Lezen

25 feb 2026, 07:06 UTC

Winsten

Haleon Declares Final Dividend of 4.9p

DJ

Lezen

25 feb 2026, 07:05 UTC

Winsten

Haleon 2025 Net Pft GBP1.67B

DJ

Lezen

25 feb 2026, 07:05 UTC

Winsten

Haleon 2025 Pretax Pft GBP2.15B

DJ

Lezen

25 feb 2026, 07:04 UTC

Winsten

Analysts Saw Haleon 2025 Adj Oper Pft at GBP2.46B

DJ

Lezen

25 feb 2026, 07:04 UTC

Winsten

Analysts Saw Haleon 2025 Adj Oper Pft Margin at 22.3%

DJ

Lezen

25 feb 2026, 07:04 UTC

Winsten

Analysts Saw Haleon 2025 Organic Revenue Growth at 3.4%

DJ

Lezen

25 feb 2026, 07:04 UTC

Winsten

Analysts Saw Haleon 2025 Rev at GBP11.03B

DJ

Lezen

25 feb 2026, 07:04 UTC

Winsten

Haleon 2025 Adj. Operating Pft Margin 22.9%

DJ

Lezen

Peer Vergelijking

Prijswijziging

Haleon PLC Prognose

Koersdoel

By TipRanks

24.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 426.67 GBX  24.1%

Hoogste 512 GBX

Laagste 325 GBX

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Haleon PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

7

Buy

2

Hold

1

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Haleon PLC - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

6 / 345 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Andere aandelen uit de sector

GSK

GlaxoSmithKline PLC

1,929.5

↑ +0.86%
help-icon Live chat